Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAVNASDAQ:BCDANASDAQ:BGXXNASDAQ:ERNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46$2.95M2.19N/AN/ABCDABioCardia$2.18-0.9%$2.24$1.63▼$4.66$11.29M0.82263,464 shs12,792 shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsERNAEterna Therapeutics$2.29-3.4%$3.03$2.08▼$39.38$142.81M5.56192,240 shs107,803 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%BCDABioCardia0.00%+0.46%-6.03%-16.15%-39.94%BGXXBright Green0.00%0.00%0.00%+60.00%-79.17%ERNAEterna Therapeutics0.00%-15.19%-34.76%-40.57%-92.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAVAraviveN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia3.6973 of 5 stars3.85.00.00.03.02.50.6BGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/AERNAEterna Therapeutics0.9068 of 5 stars0.05.00.00.01.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/ABCDABioCardia 3.50Strong Buy$25.001,046.79% UpsideBGXXBright Green 0.00N/AN/AN/AERNAEterna Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAravive$6.99M0.42N/AN/AN/A∞BCDABioCardia$3K3,762.68N/AN/A($1.11) per share-1.96BGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/AERNAEterna Therapeutics$535K266.94N/AN/A$0.41 per share5.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAravive-$76.32MN/A0.00∞N/AN/AN/AN/AN/ABCDABioCardia-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)BGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/AERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)Latest ARAV, ERNA, BCDA, and BGXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/ABCDABioCardiaN/A1.781.78BGXXBright GreenN/A0.010.01ERNAEterna TherapeuticsN/A0.480.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%BCDABioCardia20.57%BGXXBright Green7.83%ERNAEterna Therapeutics70.55%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%BCDABioCardia20.00%BGXXBright Green62.55%ERNAEterna Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive2073.56 million29.13 millionNo DataBCDABioCardia405.18 million3.67 millionOptionableBGXXBright Green2191.17 million71.59 millionNo DataERNAEterna Therapeutics1062.36 million5.17 millionNo DataARAV, ERNA, BCDA, and BGXX HeadlinesRecent News About These CompaniesErnexa Therapeutics Announces 1-for-15 Reverse Stock SplitJune 10, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025May 28, 2025 | globenewswire.comErnexa Therapeutics Stock Short Interest Report | NASDAQ:ERNA | BenzingaMay 23, 2025 | benzinga.comErnexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical OperationsMay 14, 2025 | globenewswire.comErnexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | newsfilecorp.comErnexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025April 29, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025April 22, 2025 | globenewswire.comErnexa Therapeutics files to sell 10.44M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comErnexa Therapeutics Closes New Funding RoundApril 3, 2025 | globenewswire.comEterna changes name to Ernexa TherapeuticsMarch 27, 2025 | markets.businessinsider.comEterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune DiseaseMarch 25, 2025 | markets.businessinsider.comEterna hosts inaugural meeting of newly formed SABFebruary 26, 2025 | markets.businessinsider.comEterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy PipelineFebruary 26, 2025 | globenewswire.comEterna appoints Zeldis, Sather to scientific advisory boardJanuary 29, 2025 | markets.businessinsider.comEterna Therapeutics Inc (ERNA) Stock: Beyond the Surface of Its Performance?January 23, 2025 | bovnews.comWhat’s Causing Eterna Therapeutics Inc (ERNA) Stock’s -77.77% Drop Over the Last Six Months?January 17, 2025 | bovnews.comEterna Therapeutics (NASDAQ:ERNA) Stock Quotes, Forecast and News SummaryJanuary 14, 2025 | benzinga.comEterna Announces Positive Preclinical Study Results On ERNA-101 In Ovarian Cancer; Stock Up 69%January 14, 2025 | markets.businessinsider.comEterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian CancerJanuary 14, 2025 | globenewswire.comEterna Therapeutics Appoints Dr. Elena Ratner To Board Of DirectorsJanuary 9, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International Markets3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneBy Thomas Hughes | June 4, 2025View 3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneARAV, ERNA, BCDA, and BGXX Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 06/13/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.BioCardia NASDAQ:BCDA$2.17 -0.03 (-1.36%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Eterna Therapeutics NASDAQ:ERNA$2.29 -0.08 (-3.38%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.27 -0.02 (-0.70%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
